AUG 30, 2017 10:00 AM PDT

WEBINAR: Understanding cell reprogramming in treatment-resistant prostate cancer using organoids

Speaker
  • Research Affiliate, Postdoctoral, Roswell Park Cancer Institute
    Biography
      "I completed both a Bachelors in Sciences in Molecular Genetics and a Bachelors in Arts in English with a concentration in Theater at the University of Rochester in 2009, graduating Magna Cum Laude with election to Phi Beta Kappa. I then immediately began my PhD graduate training in Pathology at the University of North Carolina at Chapel Hill, defending my dissertation in 2014, in less than 5 years.

      I published 7 manuscripts based on my dissertation work, 4 of which are first-author, on the ubiquitin proteasome system in cardiac and skeletal muscle diseases. Specifically, my work focused on muscle atrophy-associated ubiquitin ligases that regulate nuclear receptor transcription factors in cardiac hypertrophy. My dissertation work was funded by a Predoctoral grant awarded to me by the American Heart Association. In addition, I have given several oral presentations at national meetings on this topic, for which I received trainee travel grants from both the American Society for Investigative Pathology and American Physiological Society.

      I came to Roswell Park Cancer Institute in January 2015, joining the laboratory of Dr. Shahriar Koochekpour to study the mechanisms governing castration-recurrent prostate cancer. Recently, I have published three comprehensive review articles on treatment of advanced prostate cancer and therapy resistance and a research article on how the FDA-approved drug for ALS , riluzole, has anti-tumor effects in prostate cancer. In September 2016, I joined the laboratory of Dr. David Goodrich to study the mechanisms driving neuroendocrine prostate cancer. I presented my current work as a podium presentation at the 2018 Annual Meeting of the American Association for Cancer Research.

      Being a first-generation student, I am dedicated to community outreach. Especially in teaching young students with similar backgrounds about opportunities in science, technology, engineering, and math (STEM)."

    Abstract

    DATE: August 30, 2017
    TIME: 10:00am PT, 1:00pm ET

    Recent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers, such as breast, prostate, or lung, target vital pathways active in healthy tissue. The reliance of cancer cells on these pathways suggest that they retain properties of healthy cells. A prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. This therapy limits the production and effectiveness of androgen hormones because prostate cancer cells depend on androgen hormones, just like their healthy counterparts. Prostate cancers that become resistant to multiple rounds of therapy often no longer express the target of therapy. These resistant or ‘reprogrammed’ tumor cells are more likely to express different cell lineage markers. These markers are expressed by neuroendocrine cells, a rare cell type in healthy and untreated cancerous prostate tissue. Once prostate cancer cells are reprogrammed, current therapies are ineffective and patients quickly succumb to their disease. Our laboratory studies reprogramming in prostate cancer cells with the aim of developing new drugs to treat these resistant patients. We use murine models and 3D organoid culture of murine and human tumors to understand how prostate cancer cells acquire the ability to reprogram and become resistant. Organoid culture is a valuable tool in our research because it allows the formation of structures that include multiple cell types. In the future, we will use organoids of aggressive prostate cancer in screens of drug candidates and assess drug effectiveness in weeks, rather than the months or years required for classic in vivo studies. 

    Learning Objectives:

    • Understand the benefits of 3D organoid culture on modeling cancer
    • Learn about prostate cancer cell reprogramming and how the understanding of this can lead to improved therapies
       

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    AUG 30, 2017 10:00 AM PDT

    WEBINAR: Understanding cell reprogramming in treatment-resistant prostate cancer using organoids


    Specialty

    Cancer Research

    Cell Biology

    Molecular Biology

    Biotechnology

    Cell Culture

    Cancer Therapeutics

    Cancer Diagnostics

    Immunology

    Biochemistry

    Molecular Diagnostics

    Biomarkers

    Genetics

    Cell Signaling / Transduction

    Clinical Diagnostics

    Laboratory Testing

    Geography

    North America50%

    Europe15%

    Asia14%

    South America14%

    Africa2%

    Oceania1%

    Registration Source

    Website Visitors100%

    Job Title

    Student20%

    Research Scientist18%

    Educator/Faculty11%

    Facility/Department Manager7%

    Medical Laboratory Technician7%

    Executive7%

    Post Doc7%

    Scientist6%

    Medical Doctor/Specialist5%

    Biologist3%

    Clinical Laboratory Scientist3%

    Lab Management3%

    Engineer1%

    QC/QA1%

    Chemist1%

    Organization

    Academic Institution12%

    Research Institute6%

    Biotech Company5%

    Hospital5%

    Clinical Laboratory4%

    Life Science Company2%

    Medical School2%

    Government2%

    Pharmaceutical Company1%

    Ambulatory Care1%

    Consultant1%

    Contract Research Organization (Cro)1%

    Medical Device Company1%

    Industrial Company1%

    Other5%


    Show Resources
    Loading Comments...
    Show Resources